research use only

Oxysophocarpine Nrf2 inhibitor

Name: Oxysophocarpine
Brand: Selleck Chemicals
SKU: E0129
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E0129

Oxysophocarpine (OSC) is an alkaloid extracted from Sophora alopecuroides. This compound inhibits the growth and metastasis of oral squamous cell carcinoma (OSCC) by targeting the Nrf2/HO-1 axis. It protects cells against apoptosis and inflammatory responses and compromised miR-155 activity by attenuating MAPK and NF-κB pathways.

Chemical Structure

Molecular Weight: 262.35

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: E012901 DMSO]52 mg/mL]false]Water]52 mg/mL]false]Ethanol]52 mg/mL]false Purity: 99.99%

99.99

Related Targets	Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor TNF-alpha ROS Parasite PD-1/PD-L1 TLR Prostaglandin Receptor IFN CXCR NOS CCR NLRP3 eIF STING AhR IL Receptor Complement System IRAK β-lactamase IDO/TDO PGES NADPH-oxidase FKBP LTR
Related Products	ML385 Bardoxolone Methyl TBHQ Brusatol Oltipraz Bardoxolone (CDDO) 4-Octyl Itaconate CDDO-Im (RTA-403) cis-Resveratrol Mangiferin KEAP1 Antibody [L11G24] NRF2 Antibody [J1K11] KI696 Sulforaphane NK-252 HPPE CBR-470-1 BI033 Ganoderma lucidum Extract Uniflower swisscentaury root Extract Phospho-Nrf2 (Ser40) Antibody [N4G2] 5,7-Dihydroxychromone Nrf2 Antibody [N16P13] R16 L-Sulforaphane

Chemical Information, Storage & Stability

Molecular Weight	262.35	Formula	C₁₅H₂₂N₂O₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	26904-64-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	OSC			Smiles	[O-][N+]12CCCC3CN4C(CC=CC4=O)C(CCC1)C23

Solubility

In vitro
Batch:

DMSO : 52 mg/mL (198.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 52 mg/mL

Ethanol : 52 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

References	[1] https://pubmed.ncbi.nlm.nih.gov/30231242/ [2] https://pubmed.ncbi.nlm.nih.gov/32603606/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06160284	Not yet recruiting	Opioid Use Disorder	Yale University\|National Institute on Drug Abuse (NIDA)	July 2024	Phase 1
NCT05447286	Recruiting	Opioid Use Disorder	Yale University\|National Institute on Drug Abuse (NIDA)\|Aptinyx	May 15 2023	Phase 1
NCT03620578	Active not recruiting	Non Hodgkin Lymphoma\|Lymphoma B-Cell\|High-grade B-cell Lymphoma\|MYC Translocation\|BCL-2 Translocation	Stichting Hemato-Oncologie voor Volwassenen Nederland	August 1 2018	Phase 2
NCT02753764	Completed	Corticosteroid Resistant (CR) Asthmatics	National Jewish Health	January 2017	Phase 2
NCT01277874	Withdrawn	Respiratory Distress Syndrome\|Prematurity	University of Utah	December 2014	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):